Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Franklin Genomic Advancements Fund N (acc) EUR Fonds 113722568 / LU2387457729

6.37 EUR
0.02 EUR
0.32 %
9.12.2024
NAV

Nettoinventarwert (NAV)

6.37 EUR 0.02 EUR 0.32 %
Vortag 6.35 EUR Datum 09.12.2024

Franklin Genomic Advancements Fund N (acc) EUR Fonds Kurs - 1 Jahr

  • 1W
  • 3M
  • 1J
  • 3J
  • 5J
  • MAX

Top Kryptowährungen ETPs

Name ISIN Performance
21Shares Stellar ETP CH1109575535 391.18%
21Shares Sui Staking ETP CH1360612159 365.52%
21Shares Ripple XRP ETP CH0454664043 349.11%
21Shares Algorand ETP CH1146882316 263.80%
21Shares The Sandbox ETP CH1177361008 234.25%
21Shares Stacks Staking ETP CH1258969042 227.84%
21Shares Injective Staking ETP CH1360612134 110.71%
21Shares Immutable ETP CH1360612142 73.94%
Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 347.64%
21Shares Stellar ETP CH1109575535 318.27%
21Shares Aave ETP CH1135202120 156.63%
21Shares Stacks Staking ETP CH1258969042 145.10%
21Shares Algorand ETP CH1146882316 135.12%
Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 265.47%
21Shares Fantom ETP CH1168929078 254.97%
21Shares Stellar ETP CH1109575535 251.44%
21Shares Solana staking ETP CH1114873776 247.78%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 204.58%
Name ISIN Performance
21Shares Solana staking ETP CH1114873776 1’577.02%
21Shares Ripple XRP ETP CH0454664043 488.04%
21Shares Bitcoin Core ETP CH1199067674 466.59%
21Shares Bitcoin ETP CH0454664001 452.29%
21Shares Bitcoin Cash ETP CH0475552201 411.91%

Fundamentaldaten

Valor 113722568
ISIN LU2387457729
Emittent Franklin Templeton International Services
Aufgelegt in Luxembourg
Auflagedatum 15.10.2021
Kategorie Branchen: Gesundheitswesen
Währung EUR
Volumen 3’155’238.91
Depotbank J.P. Morgan SE, Luxembourg Branch
Geschäftsjahresende 30.06.
Berichtsstand 09.12.2024

Anlagepolitik

So investiert der Franklin Genomic Advancements Fund N (acc) EUR Fonds: The Fund's investment objective is capital appreciation. The Fund invests principally in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. Equity securities generally entitle the holder to participate in a company's general operating results. While the Fund invests predominantly in common stocks, it could also invest in preferred stock, convertible securities and warrants on securities.

ETP Performance: Franklin Genomic Advancements Fund N (acc) EUR Fonds

Performance 1 Jahr
10.05
Performance 2 Jahre
-4.65
Performance 3 Jahre
-35.86
Performance 5 Jahre -
Performance 10 Jahre -